These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18193075)

  • 1. Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats.
    Huntjens DR; Strougo A; Chain A; Metcalf A; Summerfield S; Spalding DJ; Danhof M; Della Pasqua O
    Br J Pharmacol; 2008 Mar; 153(5):1072-84. PubMed ID: 18193075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced plasma concentration by selective deuteration of rofecoxib in rats.
    Schneider F; Hillgenberg M; Koytchev R; Alken RG
    Arzneimittelforschung; 2006; 56(4):295-300. PubMed ID: 16724516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
    Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
    Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
    Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
    Schwartz JI; Chan CC; Mukhopadhyay S; McBride KJ; Jones TM; Adcock S; Moritz C; Hedges J; Grasing K; Dobratz D; Cohen RA; Davidson MH; Bachmann KA; Gertz BJ
    Clin Pharmacol Ther; 1999 Jun; 65(6):653-60. PubMed ID: 10391671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.
    Kim TH; Shin S; Landersdorfer CB; Chi YH; Paik SH; Myung J; Yadav R; Horkovics-Kovats S; Bulitta JB; Shin BS
    AAPS J; 2015 Sep; 17(5):1210-23. PubMed ID: 25990964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orthodontic tooth movement after inhibition of cyclooxygenase-2.
    de Carlos F; Cobo J; Díaz-Esnal B; Arguelles J; Vijande M; Costales M
    Am J Orthod Dentofacial Orthop; 2006 Mar; 129(3):402-6. PubMed ID: 16527637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy.
    Prescilla RP; Frattarelli DA; Haritos D; Aranda JV; Edwards DJ
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):661-4. PubMed ID: 15454838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
    Hinz B; Dormann H; Brune K
    Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
    Cannon GW; Caldwell JR; Holt P; McLean B; Seidenberg B; Bolognese J; Ehrich E; Mukhopadhyay S; Daniels B
    Arthritis Rheum; 2000 May; 43(5):978-87. PubMed ID: 10817549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
    Umar A; Boisseau M; Yusup A; Upur H; Bégaud B; Moore N
    Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats.
    Vásquez-Bahena DA; Salazar-Morales UE; Ortiz MI; Castañeda-Hernández G; Trocóniz IF
    Br J Pharmacol; 2010 Jan; 159(1):176-87. PubMed ID: 19958362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid and plasma pharmacokinetics of the cyclooxygenase 2 inhibitor rofecoxib in humans: single and multiple oral drug administration.
    Buvanendran A; Kroin JS; Tuman KJ; Lubenow TR; Elmofty D; Luk P
    Anesth Analg; 2005 May; 100(5):1320-1324. PubMed ID: 15845677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam.
    Harirforoosh S; Jamali F
    J Appl Toxicol; 2008 Oct; 28(7):829-38. PubMed ID: 18344196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
    Yokota A; Taniguchi M; Takahira Y; Tanaka A; Takeuchi K
    J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, placebo controlled comparison of the morphine sparing effect of oral rofecoxib and diclofenac for acute renal colic.
    Engeler DS; Ackermann DK; Osterwalder JJ; Keel A; Schmid HP
    J Urol; 2005 Sep; 174(3):933-6. PubMed ID: 16093996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men.
    Tuleja E; Mejza F; Cmiel A; Szczeklik A
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1111-5. PubMed ID: 12730088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors.
    Huntjens DR; Spalding DJ; Danhof M; Della Pasqua OE
    Eur J Pain; 2009 May; 13(5):448-57. PubMed ID: 18774319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats.
    Padi SS; Kulkarni SK
    Pharmacol Biochem Behav; 2004 Oct; 79(2):349-58. PubMed ID: 15501312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.